We are combining best in class target-optimized ASO and gapmer therapeutics with two novel delivery technologies.
Our ASO+delivery combinations can trigger gene ‘knock up’ and ‘knock down’. Our technologies are differentiated by improved targeting, penetration, and efficacy, in addition to reduced toxicity and improved muscle function.
OligomicsTx has received $100,000 for the development of its cutting-edge treatment for facioscapulohumeral muscular dystrophy (FSHD) The rare neuromuscular disease impacts 1 in 8,000 people
We are thrilled to have won at the Startup TNT Life Sciences Summit! We thank all the investors who took the time to evaluate and
Toshifumi (Toshi) Yokota, a professor of medical genetics in the Faculty of Medicine & Dentistry, has been elected as a 2023 Fellow of the Canadian Academy
Dr. Toshifumi Yokota has been selected for BioAlberta’s Scientific Achievement and Innovation Award. The award celebrates teams or individuals responsible for breakthrough innovations with commercial